FYI: Your old diet program added Foundayo eight days after approval. The 12-month contract didn't change.

Yesterday's issue covered Foundayo's slow launch and what the package insert says about women on birth control. Today we move to the contrarian beat we had originally planned for this week. We're going to walk through which industry quietly transformed itself faster than anyone in the financial press has acknowledged, what it means for anyone considering a "GLP-1 program" through a name they grew up trusting, and why one specific corporate governance fact deserves more attention than it has gotten.

This is Off Label, Not Medical Advice.

Let's go.

The Morning Read: The diet industry didn't lose to GLP-1s. It became them. The boards now include the people who launched the drugs. The contracts are still 12 months.

On May 6, 2025, WW International, the company most readers know as WeightWatchers, filed for Chapter 11 bankruptcy. Roughly $1.5 billion in legacy debt. Sixty-one years of brand history. Stock down 56% on the announcement.

On June 24, 2025, WW emerged from bankruptcy with $1.15 billion in debt eliminated and approximately $170 million in cash, relisted on Nasdaq. Less than three months later, WW's strategic identity had shifted. The "Points" program was no longer the primary growth engine. The new growth engine was a telehealth platform called WW Med+, built around the 2023 acquisition of a company called Sequence (legal name Weekend Health, Inc.) for $132 million gross / $106 million net.

WW Med+ does one thing. It connects members with board-certified clinicians who prescribe GLP-1 weight-loss medications.

Here is the timeline that matters most:

January 5, 2026: WW added Novo Nordisk's oral Wegovy pill to Med+ on the day it launched.

March 16, 2026: WW reported Q4 2025 earnings showing clinical (drug-prescribing) revenue grew 32% year-over-year while behavioral (legacy points) revenue fell 17%.

March 31, 2026: WW CEO Tara Comonte departed effective immediately, less than 14 months after her appointment to run the post-bankruptcy strategy.

April 1, 2026: FDA approved Foundayo (orforglipron), Lilly's new oral GLP-1, in 50 days under the new CNPV pilot program.

April 9, 2026: WW added Foundayo to Med+. Eight days after approval. The press release endorsing the integration was issued by Mike Mason, "a member of Weight Watchers' Board of Directors and former President of Eli Lilly's Diabetes and Obesity business."

That last sentence is the entire story. The man who ran the launch of Mounjaro and Zepbound for Eli Lilly now sits on the board of the company that decides which GLP-1s WeightWatchers members are offered. He also sits on the Transition Committee currently picking WW's next CEO.

This is the part that almost no major outlet is leading with. It is the structural story of the diet industry in 2026.

The industry has split into three groups since GLP-1s went mainstream.

Group 1 turned itself into a drug-prescribing telehealth platform with the legacy program as a wrapper. WeightWatchers (Med+) and Noom (Noom Med) are the two clearest examples. Both companies acquired or built clinical entities, contracted with prescribing physicians, and now layer the legacy behavioral content on top as differentiator and retention. Membership fees compound on top of medication fees. Insurance navigation is the hidden value driver. WW operates exclusively with FDA-approved brand-name GLP-1s after stopping its compounded semaglutide program on May 22, 2025. Noom operates compounded GLP-1s at scale and acquired its own compounding pharmacy (Tailor Made Compounding) in April 2026, per Sacra's tracking.

Group 2 chose to position itself as the GLP-1 complement, not the competitor. Medifast, parent company of OPTAVIA, is the cleanest example. Medifast launched the "OPTAVIA GLP-1 Nutrition Support Plan" in 2024 alongside a partnership with telehealth provider LifeMD for the prescribing pathway. Medifast's pitch is built around what GLP-1s do not do: preserve lean muscle, build durable habits, prevent rebound after discontinuation. CEO Dan Chard told analysts on the Q3 2025 call that "74% of patients discontinue use within a year of GLP-1 drugs, and two-thirds of the weight is regained." That is roughly accurate at the high end of published clinical literature, and Medifast is using it as the central organizing argument for its continued existence.

Group 3 is Jenny Craig. Chapter 7 bankruptcy in May 2023. Approximately 500 company-owned and franchised locations closed. C$324 million owed to unsecured creditors in Canada. The brand was sold off in pieces. This is the non-pivot. The cost of not pivoting is liquidation.

The total US weight-loss market reached an all-time high of $135 billion in 2025, per Marketdata LLC, with 38% of revenue now coming from medical programs (up from 11% in 2022 before GLP-1s went mainstream). The four major commercial diet companies as a group (WW, NutriSystem, Jenny Craig, Medifast) saw their combined revenues fall 24% in 2025 to $1.86 billion. Approximately 26,000 weight-loss coaches have lost their jobs as a direct consequence of the GLP-1 pivot.

The same Marketdata report estimates the prescription obesity drug market grew 64% in 2025, to $43.48 billion. Translation: the diet industry's customers became the drug industry's customers, and the survivors among the diet companies are the ones running the cash register at the new store.

The patient-side details that are not in the financial coverage.

WW Med+ requires a 12-month subscription commitment. The introductory offer is $25 for the first month, then $74 per month for the remaining 11 months of the term. Cancel before month 12 and the cancellation friction is substantial.

WW's BBB profile shows 989 customer complaints, 702 of them in the past 12 months. Average customer rating: 1.05 out of 5 stars. The recurring pattern in the complaints, summarized by Healthline and corroborated across Trustpilot reviews, is what reviewers describe as bait and switch: members sign up for Med+ expecting GLP-1 access, get blood work done, and are then told they do not qualify under the program's eligibility criteria. They are offered older off-label medications instead (metformin, naltrexone/bupropion). The 12-month contract still runs.

One Trustpilot review captures the pattern, edited for length: "I signed up for Weight Watchers Clinical and was told I'd qualify for GLP-1 medication. After blood work, they told me I didn't qualify unless I gained another 20 pounds. They then offered me Metformin and Wellbutrin... They refused to let me cancel."

This is the patient-side cost the financial press is not describing. The corporate pivot looks clean on a 10-K. The customer-side experience is messier than the press releases suggest.

WW Med+ membership is $25 first month, $74/month thereafter, for 12 months. The medication is billed separately. Foundayo through WW Med+ is $149 per month at the starter dose, scaling to $299 at higher doses through LillyDirect. Wegovy injectable through WW is $199 introductory then $349 cash-pay. Brand-name Zepbound or Mounjaro without insurance can exceed $1,000 per month.

For a self-pay patient on Foundayo through WW Med+, the total monthly cost ranges from approximately $223 (starter dose, after intro pricing) to $373 (highest dose plus full membership). For a self-pay patient on injectable Zepbound through WW, the total can exceed $1,000 per month all-in.

If a member's insurance covers the GLP-1 with prior authorization, the math is competitive (the WW care team handles much of the prior auth paperwork). If a member's insurance does not, the WW Med+ wrapper adds $74 per month on top of medication costs that are already direct-pay through LillyDirect or NovoCare, both of which any patient can access without a WW membership at all.

WW's marketing and press releases lean heavily on a stat: engaged Med+ members lose "29.1% more body weight" at 12 months versus medication alone. If you read the citation footnote on WW's own website, the source is identified as "Heinberg et al. Effectiveness of a Telehealth Medical Weight Management and GLP-1 Specific Behavioral Program: A 24-Week Single-arm Study. Manuscript under review. Funded by WW International, Inc."

A company-funded, single-arm, unpublished study is the marketing claim. There is a legitimate clinical question of whether structured behavioral support adds to GLP-1 outcomes, and the answer is probably yes by some amount. The amount in WW's marketing has not been peer-reviewed.

The financial press is treating WW's post-bankruptcy turnaround as a corporate comeback story. Off Label is reading it differently.

When you look at who is actually in the room making decisions for the post-bankruptcy WW, the picture changes. Mike Mason joined the WW board after running Eli Lilly's Diabetes and Obesity business through the launches of Mounjaro and Zepbound. Mason is on WW's Board of Directors. He is also on the Transition Committee currently selecting the next CEO after Tara Comonte's March 31 departure. The press release announcing Foundayo's addition to Med+ on April 9 directly quoted Mason in his role as a WW board member endorsing the integration.

This is the architecture of the entire diet-industry-as-GLP-1-channel model. WW also became a NovoCare Recognized Care Provider in early 2026, its formal designation as a preferred channel for Novo Nordisk's GLP-1s. The line between "we recommend the right drug for our member" and "we recommend the drug from our partner" is structurally compromised when board members and recognized provider designations are pulling on the same thread.

This is not unique to WW. Noom has pharmaceutical partnerships with Novo Nordisk and an integration with LillyDirect via Gifthealth. OPTAVIA partnered with LifeMD for prescribing access. Every survivor of the 2025 diet-industry shakeout has built commercial relationships into their core care model. Off Label readers should know that any time a diet program is recommending a specific GLP-1, there is a high probability that the recommendation is shaped by a commercial relationship the program does not foreground.

There is one comparison that captures the entire pivot in two numbers. WW's clinical (drug-prescribing) business grew 32% in revenue and 42% in subscribers year-over-year in Q4 2025. Its behavioral (legacy points) business shrank 17% in revenue and 19% in subscribers over the same period. The drug-related business is the only growth story. The original product is in active decline.

People are paying WW for access to the drug. They are not paying WW for the program itself.

Tie this issue back to yesterday's. If even WW with Mike Mason on its board, with NovoCare Recognized Care Provider status, with 130,000 existing clinical subscribers, and with a clinical pivot that has been the company's central marketing focus for nine months cannot push Foundayo above 3,707 prescriptions in week 2, then the slow launch is structural. It is not solvable through additional sales channels. The diet industry is not the missing distribution layer. It is already the distribution layer.

Text your doctor this: "I've been considering signing up for the WeightWatchers Med+ / Noom Med / OPTAVIA's GLP-1 plan to get a GLP-1 prescription. Before I do, I'd like to compare what they're offering against a direct prescription through your office or a non-membership telehealth provider. Specifically, I want to understand whether their behavioral support is clinically additive for me, or whether I'm better off with a direct prescription and self-directed lifestyle changes. Can we discuss the options?"

Copy, paste, send.

Tomorrow we profile a single voice in the GLP-1 conversation worth knowing. Someone whose work cuts through the marketing claims on both sides of the patient/industry debate. Different lens, different rhythm, named in the issue.

Hit reply and tell us what you want us to cover. Every reply is read. Story tips: [email protected]

See you in your inbox.

— Off Label

This is Off Label, Not Medical Advice. Content is for informational purposes only. Always consult a qualified healthcare provider before making medical decisions about starting, stopping, or modifying any prescription medication. Off Label is not anti-WeightWatchers, not anti-Noom, not anti-Medifast, and not anti-GLP-1. Each of the companies discussed in this issue offers programs that some patients value, and the clinical case for behavioral support paired with GLP-1 medications is legitimate. The thesis of this issue is that the structural realities of the diet industry's pivot, including 12-month contracts with documented cancellation friction, billing patterns reflected in BBB complaints, and corporate governance structures with direct ties to the drug manufacturers whose products the diet companies now distribute, are deserving of the same attention the financial press gives to the corporate turnaround narrative. Patients considering any commercial GLP-1 program should review the membership terms, including cancellation policy and total all-in monthly cost, before signing up.